PARI Pharma’s Altera Delivers Gilead’s Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Partner Release:
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

February 11, 2010, Monterey, California

PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Partner Press Release
Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe

Mon, 08 Feb 2010 - NESS ZIONA, Israel - (Business Wire) Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with
its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency. [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

September 23, 2009, Monterey, California

PARI’s Altera Delivers Gilead’s Cayston, Approved by European Commission to Treat Cystic Fibrosis [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

September 14, 2009, Monterey, California

Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma’s eFlow Technology [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

June 2, 2009, Monterey, California

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 20, 2009, Munich, Germany and Monterey, California

PARI Pharma’s Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

May 7, 2009, Munich, Germany and Monterey, California

PARI Pharma Receives 2nd ODD from EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward [more]

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

PARI Pharma, New Name of PARI Aerosol Research Institute [more]

January 3, 2007, Monterey, California

PARI’s eFlow Wins Good Design Award [more]

December 4, 2006, Monterey, California

NIH using PARI’s eFlow in HIV/AIDS Vaccine Research [more]

November 29, 2006, Monterey, California

PARI’s eFlow in Cystic Fibrosis Clinical Trial of L-arginine [more]

November 20, 2006, Monterey, California

PARI and Kamada Collaborate to Develop Inhaled Alpha-1 Antitrypsin [more]

October 16, 2006, Monterey, California

PARI’s eFlow Nebulizer used in Alnylam Clinical Trial for Respiratory Syncytial Virus; New Drug Based on RNAi Technology [more]

June 19, 2006, Midlothian, Virginia

PARI Named Leading Nebulizer Company in Cambridge Consulting Survey; Market Dominance Also Visible with Frost & Sullivan Award for Product Innovation [more]

May 17, 2006, Midlothian, Virginia

PARI Celebrates 100 Years of Aerosol Therapy [more]

April 10, 2006. Monterey, California

PARI Pharma receives Medical Design Excellence Award for eFlow Nebulizer [more]

April 6, 2006. Gemünden and Munich, Germany

Activaero and PARI combine technologies to create controlled breath nebulizer [more]

April 6, 2006.  Biotech Business Week

Related Kamada Press Release [more]

January 24, 2006. Monterey, California

PARI Pharma and Kamada to develop Inhaled Emphysema Therapy [more]

November 15, 2005. Monterey, California

PARI to present eFlow Development at Medical Plastics Seminar; Discussion of a Customizable Platform for New Inhaled Drug Formulations [more]

November 14, 2005. Monterey, California

PARI Issued US Patent for eFlow; Device Innovations Lead to Greater Efficiency in Drug Delivery [more]

July 29, 2005. Munich, Germany

PARI’s Inhaled Cyclosporin Granted Orphan Status in EU  [more]

October 20, 2004. Monterey, California

PARI Pharma’s Formulation Work and eFlow Featured in Corus Pharma’s Positive Phase II Trial Results -- Marks Greater Headway in Drug/Device Matching [more]

August 23, 2004. Monterey, California

PARI Granted Orphan Drug Designation for Inhaled Cyclosporine – Potential New Therapy for Lung Transplant Patients [more]

April 25, 2004. Monterey, California

Corus Pharma’s Phase III Trial for Cystic Fibrosis Drug is First to Feature PARI’s eFlow -- Marks Customization in Drug/Device Matching [more]